Protocol Ledger

NCT05563766 · Phase II · RECRUITING

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Interventional Phase II clinical trial protocol NCT05563766 sponsored by VA Office of Research and Development in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-01 Enrollment: 78 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05563766
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)78 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05563766
Protocol FieldVerified Registry Value
NCT IdentifierNCT05563766
Consolidated Lead SponsorVA Office of Research and Development
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment78 participants (ESTIMATED)
Registered Start Date2024-10-01
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI